Helen Kim

Helen Kim currently serves as the Executive Director and Head of Technology, Business Development at Amgen since March 2021, where responsibilities encompass the search, evaluation, and execution of partnerships across industry and academia, including collaborations with entities such as Carmot and institutions such as Caltech and USC. Prior to this role, Helen held the position of Director of Research at Amgen from 2010 to 2021, overseeing a multi-site team in the Genome Analysis Unit focused on the development of innovative technology platforms and the discovery of novel therapeutic targets in various research areas, including cancer biology and immunology. Helen holds a Postdoctorate in Molecular and Medical Pharmacology and a Ph.D. in Molecular Biology and Neuroscience from UCLA.